The firm has also begun an initiative to reduce and deliver sustainable revenue growth for 2019 to compensate for commercial challenges in the US market.
In a recent study, researchers found that a PSA SNP variant affected protein stability, activity, and glycosylation, and could impact clinical measurements.
CEO Kim Popovits discussed three strategic imperatives for the coming year: increasing penetration in established markets, broadening global access, and continuing to diversify its portfolio.
The assay uses a genomic DNA signature called the metastatic potential score derived from copy number alteration analysis of specific regions of the genome.
A technology called Stratification of Adverse Pathology, or STRAT-AP shows potential to risk-stratify patients using phenotypic biomarkers.
With $5.3 million in recent funding, the firm is pursuing a CE-IVD mark and planning a prospective clinical trial for its protein-based prostate cancer test.
Genomic Health will have exclusive rights to develop and sell its Oncotype DX Genomic Prostate Score test on Biocartis' Idylla platform.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
With the approval, MDxHealth can now offer its liquid biopsy molecular diagnostic assay in all 50 US states.
The company's $249.8 million in revenues missed the consensus Wall Street estimate, but its loss of $.05 per share beat analysts' average expectation.